Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Cutaneous Melanoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
8 drugs · 42 active trials
0 drugs · 0 active trials
no drug at this stage
1 drug · 11 active trials
Data updated 11 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Lifileucel | Phase 1 | Phase 1 | 2 | 0 | 0 | 3 | 0 | — | — | Feb 6, 2023 |
| Melphalan | Phase 1 | Phase 1 | 2 | 0 | 0 | 3 | 0 | — | — | Feb 6, 2023 |
| Akt Inhibitor MK2206 | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 23, 2011 |
| Hydroxychloroquine | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Nov 23, 2011 |
| Ruxolitinib | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Jun 9, 2022 |
| Abemaciclib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 29, 2016 |
| Abexinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 20, 2018 |
| Brentuximab Vedotin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 29, 2020 |
| Etoposide | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 31, 2018 |
| FACT Complex-targeting Curaxin CBL0137 | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 1, 2019 |
| Imiquimod | Phase 1 | Early Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Dec 20, 2017 |
| Obinutuzumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 28, 2020 |
| Onalespib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | May 29, 2014 |
| Pegargiminase | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-09 |
| Pegfilgrastim | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 5, 2016 |
| Ramucirumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jun 29, 2016 |
| Romidepsin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 3, 2012 |
| Sirolimus | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2012-03 |
| Tremelimumab | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 10, 2012 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.